Instalab

Valerate % Test Stool

Get an early read on whether your gut is making the lesser-known compound that fights off harmful bacteria like C. diff.

Should you take a Valerate % test?

This test is most useful if any of these apply to you.

Recovering From Recurrent Gut Infections
If you've had C. diff or repeated gut infections, this reveals whether your microbiome is producing the compound that blocks those bacteria.
Rebuilding Your Gut After Antibiotics
Antibiotics can silence the bacteria that make this compound for weeks. This test shows whether your gut chemistry has bounced back.
Living With Chronic Gut Symptoms
If bloating, loose stools, or unexplained symptoms persist after routine testing, this adds a view into the fermentation side of your gut.
Optimizing Your Microbiome Proactively
If you take prebiotics, probiotics, or follow a high-fiber diet, this offers an exploratory readout on whether those choices are changing your gut chemistry.

About Valerate %

When your gut bacteria ferment fiber, they churn out a family of compounds called short chain fatty acids, the chemicals that gut microbes make from plant fiber. Butyrate and acetate get most of the attention, but valerate (valeric acid) is the quieter cousin with an interesting job: in stool-based human research, it directly blocks the growth of Clostridioides difficile, or C. diff, the bacterium behind one of the most stubborn gut infections.

Measuring valerate in stool is a newer kind of test. It will not replace standard stool infection screens or a colonoscopy, but it hints at whether your microbiome is producing the kind of chemistry that keeps opportunistic bacteria in check. Because this marker sits on the research side of clinical medicine, your result is most useful as part of a wider short chain fatty acid picture and as a trend over time.

Why Valerate Matters

Protection Against C. diff Infection

The most notable finding for valerate comes from research on recurrent C. diff infection. In stool samples from people with recurrent infection, valerate was strongly depleted, and levels stayed low until the patients received a fecal microbiota transplant, or FMT, a treatment that transfers gut bacteria from a healthy donor. After the transplant, valerate rose back toward the range seen in healthy donors, and laboratory experiments with the same human stool samples showed that valerate at physiologic concentrations inhibited C. diff growth directly.

What this means for you: low stool valerate can look like a fingerprint of a microbiome that has stopped making its normal chemical defenses. That is relevant if you have a history of recurrent gut infection, recent heavy antibiotic exposure, or persistent gut symptoms that are hard to pin down.

Bone Density and Microbiome Chemistry

In a large human study combining microbiome sequencing with genetic analysis, the gut bacterium Bacteroides vulgatus was linked to lower bone mineral density (the measurement that defines osteoporosis risk). Valeric acid was identified as one of the metabolites on the pathway connecting the bacteria to bone biology, and higher valeric acid was associated with better bone density. The study described Bacteroides vulgatus and valeric acid as promising targets for osteoporosis prevention.

This is early-stage, exploratory evidence. A single stool valerate reading will not predict your bone density today. But it is one of the first human studies to connect a specific gut chemical to a skeletal outcome in a way that was not previously appreciated.

The Wider Short Chain Fatty Acid Picture

Short chain fatty acids as a family are tied to metabolic health, immune balance, and the integrity of the gut lining. A meta-analysis in people living with overweight and obesity found that raising short chain fatty acids, including through prebiotic fiber, reduced markers of inflammation. Valerate on its own is less studied than butyrate or acetate, so most of the broad claims about short chain fatty acids come from the family as a whole. Interpret your valerate number as one piece of that wider pattern, not a stand-alone diagnosis.

Reference Ranges

Stool valerate does not yet have standardized clinical cutpoints. Labs that report it typically express it as an absolute concentration (often as a very small amount per gram of stool) or as a percent of total short chain fatty acids, and they use reference intervals built from their own healthy donor samples. Assay method and sample handling matter, so two labs can report different numbers for identical stool. Compare your results within the same lab over time for the most meaningful trend.

In research, valerate typically makes up a small share of total short chain fatty acids in stool, with acetate, butyrate, and propionate dominating. A reading that is very low compared with healthy-donor patterns is the finding that gets the most attention, because depletion of valerate shows up in dysbiosis (an imbalance of gut bacteria) and after recurrent C. diff infection.

When Results Can Be Misleading

  • Recent antibiotics: broad-spectrum antibiotics, and clindamycin in particular, can deplete valerate-producing bacteria for weeks after the course ends. A sample taken during or just after antibiotics may show an artificially low result that is not a stable picture of your microbiome.
  • Stool transit and collection: short chain fatty acids break down if the sample sits at room temperature too long. Follow the kit's timing and freezing instructions exactly. Delayed shipping, warm weather, or a sample that was held overnight can push valerate lower than it really is.
  • Recent fiber intake: a dramatic change in fiber in the days before you collect can shift short chain fatty acid output temporarily. Test during a period that reflects your usual diet, not during a sudden elimination or fiber-loading phase.
  • Laxatives and bowel prep: recent colonoscopy prep or heavy laxative use dilutes the stool and its metabolites. Wait at least two weeks after a bowel prep before testing.

Tracking Your Trend

Because valerate is a newer research marker without consensus reference ranges, a single reading tells you relatively little. Its real value is in the pattern over time, especially if you are rebuilding your gut after antibiotics, recovering from recurrent infection, or changing diet and supplements. Get a baseline. If you are actively making changes, retest in 3 to 6 months to see if the numbers are moving. Once things stabilize, at least annual monitoring is reasonable for anyone actively managing gut health.

What to Do With an Abnormal Result

If your valerate is low, the first move is to see whether it is low in isolation or as part of a wider short chain fatty acid deficit. Order a full stool short chain fatty acid panel (acetate, butyrate, propionate, valerate together). If all four are low, that suggests general under-fermentation, often from low fiber intake or antibiotic damage. If valerate alone is low, that suggests a more specific microbial imbalance that a stool microbiome profile can help characterize.

Pair the result with calprotectin, a stool marker of gut inflammation, to see whether inflammation may be part of the picture. If you have had recurrent C. diff, unexplained diarrhea, or persistent dysbiosis despite dietary changes, a gastroenterologist familiar with microbiome testing is the right specialist to involve. Do not treat a low valerate reading as a diagnosis on its own; treat it as a signal worth investigating with a broader workup.

What Moves This Biomarker

Evidence-backed interventions that affect your Valerate % level

Increase
Fecal microbiota transplant (FMT) for recurrent C. diff infection
If your valerate is depleted because of recurrent C. diff or severe dysbiosis, FMT can restore it. In human stool samples studied before and after treatment, valerate was strongly depleted in people with recurrent C. diff infection and climbed back toward the healthy-donor range after FMT. Valerate at physiologic concentrations also directly inhibited C. diff growth in laboratory tests using the same samples.
MedicationStrong Evidence
Decrease
Broad-spectrum antibiotics, especially clindamycin
Clindamycin, a common antibiotic, wipes out many of the gut bacteria that produce valerate. In human stool samples, valerate was sharply depleted after clindamycin exposure and only recovered after fecal microbiota transplant. This depletion is one of the reasons clindamycin carries a high risk of triggering C. diff infection.
MedicationStrong Evidence
Increase
Multi-species probiotic supplementation
A 12-week randomized trial of a multi-strain probiotic in postmenopausal women with obesity increased fecal short chain fatty acids including valeric acid. The effect was modest in absolute terms but statistically significant, and the authors linked the change to reductions in a cardiovascular risk marker (blood uric acid).
SupplementModerate Evidence
Increase
Prebiotic fiber supplementation
Prebiotic fiber feeds the bacteria that make short chain fatty acids. In an open-label trial in people with Parkinson's disease, prebiotic fiber was well tolerated and produced beneficial changes in microbiota composition and stool short chain fatty acids including valerate. A separate randomized trial combining short chain fatty acids and a prebiotic improved motor symptoms in Parkinson's patients.
SupplementModerate Evidence
Increase
Energy-reduced Mediterranean diet with physical activity
A 1-year lifestyle trial combining a Mediterranean diet with increased physical activity shifted the gut metabolome in directions linked to better cardiometabolic health, including changes in short chain fatty acid-related metabolites. A separate study in people with fatty liver disease found a similar synergistic effect of Mediterranean-style eating plus activity on gut microbiota abundance and metabolites.
DietModest Evidence

Frequently Asked Questions

References

12 studies
  1. Mcdonald J, Mullish B, Pechlivanis a, Liu Z, Brignardello J, Kao D, Holmes E, Li JV, Clarke TB, Thursz M, Marchesi JGastroenterology2018
  2. Lin X, Xiao H, Liu HM, Lv WQ, Greenbaum J, Gong R, Zhang Q, Chen YC, Peng C, Xu X, Pan DY, Chen Z, Li Z, Zhou R, Wang XF, Lu JM, Ao ZX, Song YQ, Zhang YH, Su KJ, Meng XH, Ge CL, Lv FY, Luo Z, Shi X, Zhao Q, Guo B, Yi N, Shen H, Papasian C, Shen J, Deng HWNature Communications2023
  3. Blaak E, Canfora E, Theis S, Frost G, Groen a, Mithieux G, Nauta a, Scott K, Stahl B, Van Harsselaar J, Van Tol R, Vaughan E, Verbeke KBeneficial Microbes2020
  4. Vinelli V, Biscotti P, Martini D, Del Bo' C, Marino M, Meroño T, Nikoloudaki O, Calabrese FM, Turroni S, Taverniti V, Unión Caballero a, Andrés-lacueva C, Porrini M, Gobbetti M, De Angelis M, Brigidi P, Pinart M, Nimptsch K, Guglielmetti S, Riso PNutrients2022